FCGR2B and B-cell non-Hodgkin lymphoma: The importance of this finding is further supported by the fact there is an ongoing clinical trial of BI-1206, a monoclonal antibody to FCGR2B, in combination with Rituximab (chemotherapy that targets CD20) in patients with indolent B-cell non-Hodgkin lymphoma that has relapsed or is refractory to Rituximab [68].